These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 26084637)

  • 21. Incident psoriasis under treatment with tumor necrosis factor-α inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry.
    Zimmer A; Klein A; Kuemmerle-Deschner JB; Dressler F; Onken N; Brueck N; Fasshauer M; Hospach T; Hufnagel M; Foell D; Horneff G
    Rheumatol Int; 2023 Sep; 43(9):1675-1684. PubMed ID: 37291093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.
    Kearsley-Fleet L; Davies R; Baildam E; Beresford MW; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2016 Sep; 55(9):1556-65. PubMed ID: 26732349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis.
    Wulffraat NM
    Expert Opin Drug Saf; 2015; 14(12):1961-7. PubMed ID: 26568054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mechanism of action of biological disease--modifying antirheumatic drugs].
    Takahashi N; Ishiguro N
    Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
    [No Abstract]   [Full Text] [Related]  

  • 25. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.
    Horneff G; Klein A; Oommen PT; Hospach A; Foeldvari I; Feddersen I; Minden K
    Clin Exp Rheumatol; 2016; 34(6):1113-1120. PubMed ID: 27749226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on biologics in juvenile idiopathic arthritis.
    Ilowite NT
    Curr Opin Rheumatol; 2008 Sep; 20(5):613-8. PubMed ID: 18698187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.
    Berard RA; Laxer RM
    Expert Opin Biol Ther; 2013 Nov; 13(11):1623-30. PubMed ID: 24070010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing juvenile idiopathic arthritis-associated uveitis.
    Hawkins MJ; Dick AD; Lee RJ; Ramanan AV; Carreño E; Guly CM; Ross AH
    Surv Ophthalmol; 2016; 61(2):197-210. PubMed ID: 26599495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.
    Thiele F; Klein A; Windschall D; Hospach A; Foeldvari I; Minden K; Weller-Heinemann F; Horneff G
    Rheumatol Int; 2021 Apr; 41(4):751-762. PubMed ID: 33590331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
    Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
    Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologic therapies in psoriasis: a new therapeutic approach.
    Gisondi P; Girolomoni G
    Autoimmun Rev; 2007 Sep; 6(8):515-9. PubMed ID: 17854741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
    Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
    Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic therapy of psoriatic arthritis.
    Gladman DD
    Reumatismo; 2007; 59 Suppl 1():85-7. PubMed ID: 17828353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile.
    Luchetti MM; Balloni A; Gabrielli A
    Curr Drug Saf; 2016; 11(1):22-34. PubMed ID: 26463246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of juvenile idiopathic arthritis in the biologic age.
    Stoll ML; Cron RQ
    Rheum Dis Clin North Am; 2013 Nov; 39(4):751-66. PubMed ID: 24182853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database.
    Cabrera N; Lega JC; Kassai B; Wouters C; Kondi A; Cannizzaro E; Woerner A; Chausset A; Roethlisberger S; Jeanneret C; Aeschlimann F; Malik S; Duquesne A; Kaiser D; Higel L; Maes A; Berthet G; Hentgen V; Kone-Paut I; Belot A; Hofer M
    Joint Bone Spine; 2019 May; 86(3):343-350. PubMed ID: 30201476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
    Montesu MA; Addis GM; Satta R; Cottoni F
    G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
    Southwood TR; Foster HE; Davidson JE; Hyrich KL; Cotter CB; Wedderburn LR; Hull RG; Venning HE; Rahman JK; Cummins CL;
    Rheumatology (Oxford); 2011 Jan; 50(1):189-95. PubMed ID: 21047801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.